The role and assessment of ventricular peptides in heart failure

Clinics in Laboratory Medicine

Volumn 24, Issue 1, 2004, Pages 235-274

  Winter, William E ^a   Elin, Ronald J ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

CLINICAL FEATURE; COMPENSATION; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE; HUMAN; LUNG CAPILLARY PRESSURE; MEASUREMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; SWAN GANZ CATHETER; UNITED STATES; VALVULAR HEART DISEASE;

BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; NATRIURETIC PEPTIDES;

EID: 2442544485     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2004.01.011     Document Type: Review

References (130)

1. Trinity E., Apple F.S. Brain natriuretic peptide, diagnosis and management of congestive heart failure. Point of Care. 4:2002;246-252
2. Levy D., Kenchaiah S., Larson M.G., Benjamin E.J., Kupka M.J., Ho K.K., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 347:(18):2002;1397-1402
3. Redfield M.M. Heart failure - an epidemic of uncertain proportions. N Engl J Med. 347:(18):2002;1442-1444
4. Adams K.F. Jr. New epidemiologic perspectives concerning mild-to-moderate heart failure. Am J Med. 110:(Suppl 7A):2001;6S-13S
5. Wu A.H. Laboratory markers of CHF. Advance/Laboratory 2002. 2002;Merion Publishers, King of Prussia (PA)
6. Rolfo C., Bobbio M., Brossa C., Bisi G., Trevi G.P. One year temporal pattern of neurohumoral factors and natriuretic peptides compared with clinical variables in patients with dilated cardiomyopathy. Minerva Cardioangiol. 50:(6):2002;661-665
7. Braunwald E. The Denolin lecture. Congestive heart failure: a half century perspective. Eur Heart J. 22:(10):2001;825-836
8. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med. 345:(23):2001;1689-1697
9. Baughman K.L. B-type natriuretic peptide-a window to the heart. N Engl J Med. 347:(3):2002;158-159
10. Mair J., Friedl W., Thomas S., Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl. 230:1999;132-142
11. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease? Clin Chem Lab Med. 40:(8):2002;752-760
12. Sagnella G.A. Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem. 38:(Pt 2):2001;83-93
13. Hunt P.J., Espiner E.A., Nicholls M.G., Richards A.M., Yandle T.G. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides. 18:(10):1997;1475-1481
14. Goetze J.P., Kastrup J., Pedersen F., Rehfeld J.F. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem. 48:(7):2002;1035-1042
15. Luchner A., Hengstenberg C., Lowel H., Trawinski J., Baumann M., Riegger G.A., et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension. 39:(1):2002;99-104
16. Shimizu H., Masuta K., Aono K., Asada H., Sasakura K., Tamaki M., et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta. 316:(1-2):2002;129-135
17. Cataliotti A., Malatino L.S., Jougasaki M., Zoccali C., Castellino P., Giacone G., et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc. 76:(11):2001;1111-1119
18. Downie P.F., Talwar S., Squire I.B., Davies J.E., Barnett D.B., Ng L.L. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci (Lond). 97:(3):1999;255-258
19. Remme W.J., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 22:(17):2001;1527-1560
20. McKee P.A., Castelli W.P., McNamara P.M., Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 285:(26):1971;1441-1446
21. Carlson K.J., Lee D.C., Goroll A.H., Leahy M., Johnson R.A. An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients. J Chronic Dis. 38:(9):1985;733-739
22. Remes J., Miettinen H., Reunanen A., Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 12:(3):1991;315-321
23. Mair J. Role of cardiac natriuretic peptide testing in heart failure. Clin Chem. 48:2002;977-978
24. Cabanes L., Richaud-Thiriez B., Fulla Y., Heloire F., Vuillemard C., Weber S., et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest. 120:(6):2001;2047-2050
25. Bettencourt P., Ferreira A., Dias P., Castro A., Martins L., Cerqueira-Gomes M. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology. 93:(1-2):2000;19-25
26. Logeart D., Saudubray C., Beyne P., Thabut G., Ennezat P.V., Chavelas C., et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol. 40:(10):2002;1794-1800
27. Masson S., Vago T., Baldi G., Salio M., De Angelis N., Nicolis E., et al. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med. 40:(8):2002;761-763
28. Hunt P.J., Yandle T.G., Nicholls M.G., Richards A.M., Espiner E.A. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun. 214:(3):1995;1175-1183
29. Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., Espiner E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 47:(3):1997;287-296
30. Schulz H., Langvik T.A., Lund Sagen E., Smith J., Ahmadi N., Hall C. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand J Clin Lab Invest. 61:(1):2001;33-42
31. Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med. 3:(Suppl 4):2002;S10-S17
32. Lee S.C., Stevens T.L., Sandberg S.M., Heublein D.M., Nelson S.M., Jougasaki M., et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail. 8:(3):2002;149-154
33. Tabbibizar R., Maisel A. The impact of B-type natriuretic peptide levels on the diagnoses and management of congestive heart failure. Curr Opin Cardiol. 17:(4):2002;340-345
34. Yandle T., Fisher S., Espiner E., Richards M., Nicholls G. Validating aminoterminal BNP assays: a word of caution. Lancet. 353:(9158):1999;1068-1069
35. Cowie M.R., Struthers A.D., Wood D.A., Coats A.J., Thompson S.G., Poole-Wilson P.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:(9088):1997;1349-1353
36. McGeoch G., Lainchbury J., Town G.I., Toop L., Espiner E., Richards A.M. Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur J Heart Fail. 4:(4):2002;479-483
37. Yamamoto K., Burnett J.C. Jr., Bermudez E.A., Jougasaki M., Bailey K.R., Redfield M.M. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail. 6:(3):2000;194-200
38. Kruger S., Graf J., Kunz D., Stickel T., Hanrath P., Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol. 40:(4):2002;718-722
39. Ogawa K., Oida A., Sugimura H., Kaneko N., Nogi N., Hasumi M., et al. Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients: comparison of electrocardiography, chest radiography and echocardiography. Circ J. 66:(2):2002;122-126
40. Talwar S., Squire I.B., Davies J.E., Barnett D.B., Ng L.L. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J. 20:(23):1999 Dec;1736-1744
41. Talwar S., Siebenhofer A., Williams B., Ng L. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Heart. 83:(3):2000;278-282
42. Campbell D.J., Mitchelhill K.I., Schlicht S.M., Booth R.J. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction. J Card Fail. 6:(2):2000;130-139
43. Talwar S., Downie P.F., Squire I.B., Davies J.E., Barnett D.B., Ng L.L. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail. 3:(1):2001;15-19
44. Dudek D., Rzeszutko L., Petkow Dimitrow P., Bartus S., Sorysz D., Chyrchel M., et al. Circulating N-terminal brain natriuretic peptide precursor and endothelin levels in patients with syndrome X and left bundle branch block with preserved systolic function. Int J Cardiol. 79:(1):2001;25-30
45. Groenning B.A., Nilsson J.C., Sondergaard L., Pedersen F., Trawinski J., Baumann M., et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J. 143:(5):2002;923-929
46. Pfister R., Scholz M., Wielckens K., Erdmann E., Schneider C.A. The value of natriuretic peptides NT-pro-BNP and BNP for the assessment of left-ventricular volume and function. A prospective study of 150 patients. Dtsch Med Wochenschr. 127:(49):2002;2605-2609
47. Hammerer-Lercher A., Neubauer E., Muller S., Pachinger O., Puschendorf B., Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta. 310:(2):2001;193-197
48. Struthers A.D. How to use natriuretic peptide levels for diagnosis and prognosis. Eur Heart J. 20:(19):1999;1374-1375
49. Ono M., Tanabe K., Asanuma T., Yoshitomi H., Shimizu H., Ohta Y., et al. Doppler echocardiography-derived index of myocardial performance (TEI index): comparison with brain natriuretic peptide levels in various heart disease. Jpn Circ J. 65:(7):2001;637-642
50. Bayes-Genis A., Conover C.A., Overgaard M.T., Bailey K.R., Christiansen M., Holmes D.R. Jr., et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 345:(14):2001;1022-1029
51. Bhagavan N.V., Lai E.M., Rios P.A., Yang J., Ortega-Lopez A.M., Shinoda H., et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem. 49:(4):2003;581-585
52. Darbar D., Davidson N.C., Gillespie N., Choy A.M., Lang C.C., Shyr Y., et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol. 78:(3):1996;284-287
53. Arakawa N., Nakamura M., Aoki H., Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol. 27:(7):1996;1656-1661
54. Richards A.M., Nicholls M.G., Yandle T.G., Ikram H., Espiner E.A., Turner J.G., et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart. 81:(2):1999;114-120
55. de Lemos J.A., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 345:(14):2001;1014-1021
56. de Lemos J.A., Morrow D.A. B-type natriuretic peptide and acute coronary syndromes. N Engl J Med. 346:2002;453-454
57. Sabatine M.S., Morrow D.A., de Lemos J.A., Gibson C.M., Murphy S.A., Rifai N., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 105:(15):2002;1760-1763
58. Inoue T., Sakuma M., Yaguchi I., Mizoguchi K., Uchida T., Takayanagi K., et al. Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. Am Heart J. 143:(5):2002;790-796
59. Nakamura T., Sakamoto K., Yamano T., Kikkawa M., Zen K., Hikosaka T., et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 39:(10):2002;1657-1663
60. Richards A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 97:(19):1998;1921-1929
61. Talwar S., Squire I.B., Downie P.F., Davies J.E., Ng L.L. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart. 84:(4):2000;421-424
62. Omland T., de Lemos J.A., Morrow D.A., Antman E.M., Cannon C.P., Hall C., et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 89:(4):2002;463-465
63. Omland T., Persson A., Ng L., O'Brien R., Karlsson T., Herlitz J., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 106:(23):2002;2913-2918
64. Jernberg T., Stridsberg M., Venge P., Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 40:(3):2002;437-445
65. Nilsson J.C., Groenning B.A., Nielsen G., Fritz-Hansen T., Trawinski J., Hildebrandt P.R., et al. Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. Am Heart J. 143:(4):2002;696-702
66. Hartmann F., Kurowski V., Maghsoudi A., Kurz T., Schwarz M., Bonnemeier H., et al. Plasma catecholamines and N-terminal proBNP in patients with acute myocardial infarction undergoing primary angioplasty. Relation to left ventricular function and clinical outcome. Z Kardiol. 92:(1):2003;73-81
67. Struthers A.D. N-terminal proBNP - the most cost effective way to identify post infarction left ventricular dysfunction? Eur Heart J. 21:(18):2000;1490-1492
68. Campbell D.J., Munir V., Hennessy O.F., Dent A.W. Plasma amino-terminal pro-brain natriuretic peptide levels in subjects presenting to the emergency department with suspected acute coronary syndrome: possible role in selecting patients for follow up? Intern Med J. 31:(4):2001;211-219
69. Kazanegra R., Cheng V., Garcia A., Krishnaswamy P., Gardetto N., Clopton P., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 7:(1):2001;21-29
70. Murdoch D.R., McDonagh T.A., Byrne J., Blue L., Farmer R., Morton J.J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 138:(6 Pt 1):1999;1126-1132
71. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 355:(9210):2000;1126-1130
72. Richards A.M., Lainchbury J.G., Nicholls M.G., Troughton R.W., Yandle T.G. BNP in hormone-guided treatment of heart failure. Trends Endocrinol Metab. 13:(4):2002;151-155
73. Nicholls M.G., Lainchbury J.G., Richards A.M., Troughton R.W., Yandle T.G. Brain natriuretic peptide-guided therapy for heart failure. Ann Med. 33:(6):2001;422-427
74. McDonagh T.A., Robb S.D., Murdoch D.R., Morton J.J., Ford I., Morrison C.E., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 351:(9095):1998;9-13
75. Nakamura M., Endo H., Nasu M., Arakawa N., Segawa T., Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart. 87:(2):2002;131-135
76. Vasan R.S., Benjamin E.J., Larson M.G., Leip E.P., Wang T.J., Wilson P.W., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA. 288:(10):2002;1252-1259
77. Hobbs F.D., Davis R.C., Roalfe A.K., Hare R., Davies M.K., Kenkre J.E. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ. 324:(7352):2002;1498
78. Bay M., Kirk V., Parner J., Hassager C., Nielsen H., Krogsgaard K., et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart. 89:(2):2003;150-154
79. Maeda K., Tsutamoto T., Wada A., Mabuchi N., Hayashi M., Tsutsui T., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 36:(5):2000;1587-1593
80. Cheng V., Kazanagra R., Garcia A., Lenert L., Krishnaswamy P., Gardetto N., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 37:(2):2001;386-391
81. Hulsmann M., Berger R., Sturm B., Bojic A., Woloszczuk W., Bergler-Klein J., et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J. 23:(11):2002;886-891
82. Koglin J., Pehlivanli S., Schwaiblmair M., Vogeser M., Cremer P., vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 38:(7):2001;1934-1941
83. Ishii J., Nomura M., Nakamura Y., Naruse H., Mori Y., Ishikawa T., et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol. 89:(6):2002;691-695
84. Berger R., Huelsman M., Strecker K., Bojic A., Moser P., Stanek B., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 105:(20):2002;2392-2397
85. Sodian R., Loebe M., Schmitt C., Potapov E.V., Siniawski H., Muller J., et al. Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol. 38:(7):2001;1942-1949
86. Naganuma T., Sugimura K., Wada S., Yasumoto R., Sugimura T., Masuda C., et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol. 22:(5-6):2002;437-444
87. Goto T., Takase H., Toriyama T., Sugiura T., Kurita Y., Tsuru N., et al. Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron. 92:(3):2002;610-615
88. Nakatani T., Naganuma T., Masuda C., Uchida J., Sugimura T., Sugimura K. Significance of brain natriuretic peptides in patients on continuous ambulatory peritoneal dialysis. Int J Mol Med. 10:(4):2002;457-461
89. Snowden J.A., Hill G.R., Hunt P., Carnoutsos S., Spearing R.L., Espiner E., et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant. 26:(3):2000;309-313
90. Suzuki M., Hamada M., Yamamoto K., Kazatani Y., Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res. 25:(5):2002;669-676
91. Mori K., Manabe T., Nii M., Hayabuchi Y., Kuroda Y., Tatara K. Plasma levels of natriuretic peptide and echocardiographic parameters in patients with Duchenne's progressive muscular dystrophy. Pediatr Cardiol. 23:(2):2002;160-166
92. Richards A.M., Doughty R., Nicholls M.G., MacMahon S., Sharpe N., Murphy J., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 37:(7):2001;1781-1787
93. Tulevski I.I., Mulder B.J., van Veldhuisen D.J. Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism. J Am Coll Cardiol. 39:(12):2002;2080
94. Tulevski I.I., Hirsch A., Sanson B.J., Romkes H., van der Wall E.E., van Veldhuisen D.J., et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost. 86:(5):2001;1193-1196
95. Nagaya N., Ando M., Oya H., Ohkita Y., Kyotani S., Sakamaki F., et al. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg. 74:(1):2002;180-184
96. Matsuo K., Nishikimi T., Yutani C., Kurita T., Shimizu W., Taguchi A., et al. Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. Circulation. 98:(22):1998;2433-2440
97. Katsukida K., Kisanuki A., Toyonaga K., Murayama T., Nakashima H., Kumanohoso T., et al. Comparison of transthoracic Doppler echocardiography and natriuretic peptides in predicting mean pulmonary capillary wedge pressure in patients with chronic atrial fibrillation. J Am Soc Echocardiogr. 14:(11):2001;1080-1087
98. Ohta Y., Shimada T., Yoshitomi H., Inoue S., Murakami Y., Shimizu H., et al. Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol. 17:(4):2001;415-420
99. Shimizu H., Murakami Y., Inoue S., Ohta Y., Nakamura K., Katoh H., et al. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke. 33:(4):2002;1005-1010
100. Ationu A., Carter N.D. Brain and atrial natriuretic peptide plasma concentrations in normal healthy children. Br J Biomed Sci. 50:(2):1993;92-95
101. Yoshibayashi M., Kamiya T., Saito Y., Nakao K., Nishioka K., Temma S., et al. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol. 133:(2):1995;207-209
102. Muta H., Ishii M., Maeno Y., Akagi T., Kato H. Quantitative evaluation of the changes in plasma concentrations of cardiac natriuretic peptide before and after transcatheter closure of atrial septal defect. Acta Paediatr. 91:(6):2002;649-652
103. Puddy V.F., Amirmansour C., Williams A.F., Singer D.R. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond). 103:(1):2002;75-77
104. Hayakawa H., Komada Y., Hirayama M., Hori H., Ito M., Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 37:(1):2001;4-9
105. Mir T.S., Marohn S., Laer S., Eiselt M., Grollmus O., Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics. 110:(6):2002;E76
106. Fleming S.M., O'Gorman T., O'Byrne L., Grimes H., Daly K.M., Morrison J.J. Cardiac troponin I and N-terminal pro-brain natriuretic peptide in umbilical artery blood in relation to fetal heart rate abnormalities during labor. Pediatr Cardiol. 22:(5):2001;393-396
107. Fischer Y., Filzmaier K., Stiegler H., Graf J., Fuhs S., Franke A. Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide. Clin Chem. 47:(3):2001;591-594
108. Tjeerdsma G., de Boer R.A., Boomsma F., van den Berg M.P., Pinto Y.M., van Veldhuisen D.J. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int J Cardiol. 86:(2-3):2002;143-149
109. Maisel A.S., Koon J., Krishnaswamy P., Kazenegra R., Clopton P., Gardetto N., et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 141:(3):2001;367-374
110. Dao Q., Krishnaswamy P., Kazanegra R., Harrison A., Amirnovin R., Lenert L., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 37:(2):2001;379-385
111. Morrison L.K., Harrison A., Krishnaswamy P., Kazanegra R., Clopton P., Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 39:(2):2002;202-209
112. Wieczorek S.J., Wu A.H., Christenson R., Krishnaswamy P., Gottlieb S., Rosano T., et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J. 144:(5):2002;834-839
113. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347:(3):2002;161-167
114. McCullough P.A., Nowak R.M., McCord J., Hollander J.E., Herrmann H.C., Steg P.G., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 106:(4):2002;416-422
115. Lubien E., DeMaria A., Krishnaswamy P., Clopton P., Koon J., Kazanegra R., et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 105:(5):2002;595-601
116. Park M.H., Scott R.L., Uber P.A., Harris B.C., Chambers R., Mehra M.R. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. Am J Cardiol. 90:(12):2002;1326-1329
117. Maisel A.S. B-type natriuretic peptide (BNP) levels: diagnostic and therapeutic potential. Rev Cardiovasc Med. 2:(Suppl 2):2001;S13-S18
118. Clerico A., Iervasi G., Del Chicca M.G., Emdin M., Maffei S., Nannipieri M., et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest. 21:(3):1998;170-179
119. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett J.C. Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 40:(5):2002;976-982
120. Roche Diagnostics. Product insert 03121640. Indianapolis (IN); 2003.
121. Kato J., Kitamura K., Uemura T., Kuwasako K., Kita T., Kangawa K., et al. Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res. 25:(6):2002;887-892
122. Nageh T., Chin D., Cooke J.C., Meehan N., Monaghan M.J., Sherwood R.A. Interpretation of plasma brain natriuretic peptide concentrations may require adjustment for patient's age. Ann Clin Biochem. 39:(Pt 2):2002;151-153
123. McNairy M., Gardetto N., Clopton P., Garcia A., Krishnaswamy P., Kazanegra R., et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J. 143:(3):2002;406-411
124. Huang W.S., Lee M.S., Perng H.W., Yang S.P., Kuo S.W., Chang H.D. Circulating brain natriuretic peptide values in healthy men before and after exercise. Metabolism. 51:(11):2002;1423-1426
125. Almeida S.S., Azevedo A., Castro A., Frioes F., Freitas J., Ferreira A., et al. B-type natriuretic peptide is related to left ventricular mass in hypertensive patients but not in athletes. Cardiology. 98:(3):2002;113-115
126. Jensen K.T., Carstens J., Ivarsen P., Pedersen E.B. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest. 57:(6):1997;529-540
127. Shimizu H., Aono K., Masuta K., Asada H., Misaki A., Teraoka H. Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. Clin Chim Acta. 305:(1-2):2001;181-186
128. Bluestein B.I., Despres N., Belenky A., Ghani F., Armstrong E.G. BNP in the diagnosis of heart failure. Advance/Laboratory. 12:(4):2003;63-72
129. Haug C., Metzele A., Steffgen J., Kochs M., Hombach V., Grunert A. Increased brain natriuretic peptide and atrial natriuretic peptide plasma concentrations in dialysis-dependent chronic renal failure and in patients with elevated left ventricular filling pressure. Clin Investig. 72:(6):1994;430-434
130. Qi W., Mathisen P., Kjekshus J., Simonsen S., Endresen K., Bjornerheim R., et al. The effect of aortic valve replacement on N-terminal natriuretic propeptides in patients with aortic stenosis. Clin Cardiol. 25:(4):2002;174-180